Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $524,706.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 21,700 shares of the company’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $24.18, for a total transaction of $524,706.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Anish Patel also recently made the following trade(s):

• On Friday, October 18th, Anish Patel sold 716 shares of Enliven Therapeutics stock. The shares were sold at an average price of $30.00, for a total value of $21,480.00.

Enliven Therapeutics Price Performance

NASDAQ ELVN opened at $21.74 on Monday. Enliven Therapeutics, Inc. has a 1-year low of $10.90 and a 1-year high of $30.03. The company has a market cap of $1.06 billion, a PE ratio of -11.44 and a beta of 1.04. The stock’s 50 day simple moving average is $24.54 and its 200-day simple moving average is $24.43.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Robert W. Baird increased their price target on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th. BTIG Research initiated coverage on shares of Enliven Therapeutics in a research note on Friday, December 13th. They issued a “buy” rating and a $42.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $37.00 price target on shares of Enliven Therapeutics in a report on Tuesday, October 1st. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $38.25.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quest Partners LLC raised its position in shares of Enliven Therapeutics by 87.3% in the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock valued at $37,000 after buying an additional 742 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Enliven Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock valued at $232,000 after acquiring an additional 3,559 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Enliven Therapeutics in the 3rd quarter valued at about $256,000. Verition Fund Management LLC purchased a new position in Enliven Therapeutics in the 3rd quarter worth approximately $271,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Enliven Therapeutics during the 2nd quarter worth approximately $322,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.